GlassScriptPhysician profile
Andrew J Toscano
NPI 1063738318
$752.15
in general payments reported to CMS, 2019-2025
10 companies · $84.09 in 2025
The $84.09 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.08 · 2020: $55.11 · 2021: $123 · 2022: $94.46 · 2023: $153 · 2024: $203 · 2025: $84.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $440.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $503.69 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $69.05 | 2021-2022 | |
| Grifols USA, LLC | $39.43 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.26 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $27.73 | 2020-2022 | |
| Tersera Therapeutics LLC | $26.45 | 2021 | |
| Verona Pharma, INC. | $16.11 | 2025 | Ohtuvayre |
| Optinose US, INC. | $14.42 | 2020 | |
| Portola Pharmaceuticals, LLC | $14.27 | 2020 | |
| Jazz Pharmaceuticals INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Toscano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.